Weill Cornell Breast Center

01/07/2026

Congratulations to Dr. Vered Stearns who was appointed as the NRG Oncology Translational Science Committee Chair starting March 1, 2026! https://bit.ly/4piHNfD

12/18/2025

Via OncLive: Dr. Massimo Cristofanilli weighed in on data from presented at with the potential to change practice:

Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.

12/16/2025

Recruitment has begun for a led by Dr. Massimo Cristofanilli aimed at evaluating the performance of a screening test: https://bit.ly/48HVzni

12/12/2025

ICYMI: Dr. Massimo Cristofanilli recently joined the Weill Cornell Medicine podcast to share his expertise into how liquid biopsies, ctDNA, and CTCs can provide real-time insights into 🔍🩸

Podcast Episode · CancerCast · 11/21/2025 · 1 sec

10/21/2025

The Butterfield Market and Catering cake is back! Proceeds from the cake support at Weill Cornell Medicine. The cake can be purchased at both Butterfield Market locations through the end of October.

10/20/2025

10/13/2025

This , join the Weill Cornell Medicine/NewYork-Presbyterian Hospital Breast Center team for the Woman-to-Women Conference on 10/21 featuring patient speakers. Connect with others who are undergoing or have completed treatment. More details below.

09/24/2025

Hear Weill Cornell Medicine Chief of Breast Surgery Dr. Lisa Newman talk about how her experiences have shaped her and care perspectives when caring for patients:

BCRF investigator Dr. Lisa Newman talks about the personal experiences that have shaped her research and career.

06/25/2025

WATCH: Dr. Massimo Cristofanilli spoke with CURE Today about targeting ESR1 mutations early on in an effort to improve outcomes

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

06/20/2025

“This is the proof that precision medicine is changing the practice of breast oncology,” said Dr. Massimo Cristofanilli, discussing presented at on the use of camizestrant at detection of ESR1 mutations in advanced patients.

CHICAGO — Testing for ESR1 mutations during first-line treatment of ER-positive, HER2-negative advanced breast cancer could allow for early intervention to improve survival, according to results of a randomized phase 3 trial.The findings, presented at ASCO Annual Meeting and simultaneously pub...

06/05/2025

Dr. Massimo Cristofanilli was involved with presented at and concurrently published in The New England Journal of Medicine on the use of liquid biopsy blood tests to detect treatment-resistant mutations in a subset of .

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compar...

05/09/2025

The oncology team sat NewYork-Presbyterian Hospital Brooklyn hosts an art open house each year to display art created by patients as part of the HEART (Healing and Empowerment through ART) program, which offers free art classes for patients:

At the Meyer Cancer Center at NewYork-Presbyterian Brooklyn Methodist Hospital, an annual art show spotlights the work of cancer patients who found solace and inspiration in creative expression.